Define euglycemic diabetic ketoacidosis and discuss its risks in patients using SGLT2 inhibitors.

• A. Diabetic ketoacidosis with glucose levels above 300 mg/dL.
• B. Diabetic ketoacidosis with normal or near-normal glucose (<250 mg/dL).
• C. SGLT2 inhibitors prevent diabetic ketoacidosis.
• D. Diabetic ketoacidosis cannot occur in type 2 diabetes patients on SGLT2 inhibitors.

Answer: (B)